Publication:
Real-World Effectiveness and Safety of Sacituzumab Govitecan in Patients With Metastatic or Unresectable Locally Advanced Triple-Negative Breast Cancer: A Multicenter Study by the Turkish Oncology Group

Simple item page
dc.authorwosidAsik, Esra/Lzf-6701-2025
dc.authorwosidHacıbekiroğlu, İlhan/Jcn-7264-2023
dc.authorwosidDemir, Bilgin/Grx-2032-2022
dc.authorwosidAytaç, Ali̇/Hkn-0010-2023
dc.authorwosidTunbekici, Salih/Mzr-6469-2025
dc.authorwosidGuliyev, Murad/Jgm-6815-2023
dc.authorwosidDuzkopru, Yakup/Glt-1944-2022
dc.contributor.authorTunbekici, Salih
dc.contributor.authorSahin, Gokhan
dc.contributor.authorOn, Sercan
dc.contributor.authorOruc, Ahmet
dc.contributor.authorEryilmaz, Melek Karakurt
dc.contributor.authorSakin, Abdullah
dc.contributor.authorGoker, Erdem
dc.date.accessioned2025-12-11T00:49:10Z
dc.date.issued2025
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Tunbekici, Salih; Sahin, Gokhan; On, Sercan; Yildirim, Hasan Cagri; Gursoy, Pinar; Goker, Erdem] Ege Univ, Dept Med Oncol, Med Fac, Izmir, Turkiye; [Oruc, Ahmet; Eryilmaz, Melek Karakurt] Necmettin Erbakan Univ, Dept Med Oncol, Meram Med Fac Hosp, Konya, Turkiye; [Sakin, Abdullah] Istanbul Medipol Univ, Medipol Bahcelievler Hosp, Dept Med Oncol, Istanbul, Turkiye; [Coskun, Alper] Uludag Univ, Dept Med Oncol, Bursa, Turkiye; [Seyyar, Mustafa] Gaziantep City Hosp, Dept Med Oncol, Gaziantep, Turkiye; [Uzundere, Fatma Keskin] Dicle Univ, Med Sch, Med Oncol, Diyarbakir, Turkiye; [Kolemen, Erdem; Cabuk, Devrim] Kocaeli Univ, Dept Med Oncol, Fac Med Hosp, Kocaeli, Turkiye; [Efil, Safa Can; Sendur, Mehmet Ali Nahit] Etlik City Hosp, Dept Med Oncol, Ankara, Turkiye; [Demir, Teyfik] Ondokuz Mayis Univ, Dept Med Oncol, Fac Med, Samsun, Turkiye; [Turkmen, Emine; Ekinci, Ferhat] Celal Bayar Univ, Fac Med, Dept Med Oncol, Manisa, Turkiye; [Terzi, Aytac] 9 Eylul Univ, Dept Med Oncol, Fac Med, Izmir, Turkiye; [Sahin, Taha Koray; Guven, Deniz Can; Aksoy, Sercan] Hacettepe Univ, Dept Med Oncol, Canc Inst, Ankara, Turkiye; [Aytac, Ali] Mehmet Akif Inan Training & Res Hosp, Dept Med Oncol, Sanliurfa, Turkiye; [Demirkiran, Ozge; Demir, Bilgin] Aydin Adnan Menderes Univ, Fac Med, Dept Med Oncol, Aydin, Turkiye; [Culcuoglu, Ismet; Ersoy, Mustafa] Kutahya City Hosp, Dept Med Oncol, Kutahya, Turkiye; [Asarkaya, Esra] Cukurova Univ, Dept Med Oncol, Adana, Turkiye; [Camanli, Ufuk; Gezici, Baris] Izmir City Hosp, Dept Med Oncol, Izmir, Turkiye; [Ozveren, Ahmet] Izmir Kent Hosp, Med Oncol Dept MD, Izmir, Turkiye; [Sevinc, Alper] Med Pk Gaziantep Hosp, Med Oncol, Gaziantep, Turkiye; [Kitapli, Sait] Mugla Sitki Kocman Univ Training & Res Hosp, Dept Med Oncol, Mugla, Turkiye; [Unlu, Ahmet; Ozturk, Banu] Antalya Training & Res Hosp, Dept Med Oncol, Antalya, Turkiye; [Turkel, Alper; Dogan, Mutlu] Dr Abdurrahman Yurtaslan Ankara Oncol Training & R, Dept Med Oncol, Ankara, Turkiye; [Aslan, Ferit] Medicalpk Ankara Batikent Hosp, Dept Med Oncol, Ankara, Turkiye; [Yesilbas, Enes] Ankara Etlik City Hosp, Dept Med Oncol, Ankara, Turkiye; [Kaplan, Esmanur] Univ Hlth Sci, Gulhane Training & Res Hosp, Dept Med Oncol, Ankara, Turkiye; [Sakalar, Teoman] Kahramanmaras Sutcu Imam Univ, Fac Med, Dept Med Oncol, Kahramanmaras, Turkiye; [Sahin, Elif] Kocaeli City Hosp, Dept Med Oncol, Kocaeli, Turkiye; [Emin, Gamze; Asik, Esra; Yildirim, Atilla] Karadeniz Tech Univ, Fac Med, Dept Med Oncol, Trabzon, Turkiye; [Guclu, Taliha] Pamukkale Univ, Fac Med, Dept Med Oncol, Denizli, Turkiye; [Ugurlu, Irem; Kahvecioglu, Fatma; Hacibekiroglu, Ilhan] Sakarya Training & Res Hosp, Dept Med Oncol, Sakarya, Turkiye; [Tunbekici, Ibrahim] Cukurova Univ, Dept Plast Reconstruct & Aesthet Surg, Fac Med Hosp, Adana, Turkiye; [Bayram, Selami] Mem Antalya Hosp, Dept Med Oncol, Antalya, Turkiye; [Kaya, Ali Osman] Medicana Beylikduzu Hosp, Dept Med Oncol, Istanbul, Turkiye; [Majidova, Nargiz] Med Pk Maltepe Hosp, Dept Med Oncol, Istanbul, Turkiye; [Yalici, Ozge] Tekirdag Namik Kemal Univ, Dept Med Oncol, Fac Med Hosp, Tekirdag, Turkiye; [Karateke, Murat] Manisa City Hosp, Dept Med Oncol, Manisa, Turkiye; [Avci, Nilufer] Medicana Bursa Hosp, Dept Med Oncol, Bursa, Turkiye; [Belen, Burcu] Tekirdag Dr Ismail Fehmi Cumalioglu City Hosp, Dept Med Oncol, Tekirdag, Turkiye; [Bal, Hamit; Kinikoglu, Oguzcan] Kartal City Hosp, Dept Med Oncol, Istanbul, Turkiye; [Turkoz, Fatma Paksoy] Med Pk Goztepe Hosp, Dept Med Oncol, Istanbul, Turkiye; [Simsek, Eda Tanrikulu] Anadolu Med Ctr, Dept Med Oncol, Kocaeli, Turkiye; [Altinok, Oguz] Bakirkoy Dr Sadi Konuk Training & Res Hosp, Dept Med Oncol, Istanbul, Turkiye; [Gunes, Tugce Kubra; Altintas, Yunus Emre] Umraniye City Hosp, Dept Med Oncol, Istanbul, Turkiye; [Guliyev, Murad] Istanbul Univ Cerrahpasa, Cerrahpasa Fac Med Hosp, Dept Med Oncol, Istanbul, Turkiye; [Ozturk, Gokhan] Trakya Univ, Dept Med Oncol, Fac Med Hosp, Edirne, Turkiye; [Erdem, Dilek] Istinye Univ, Dept Med Oncol, Fac Med Hosp, Istanbul, Turkiye; [Duzkopru, Yakup] Aksaray Training & Res Hosp, Dept Med Oncol, Aksaray, Turkiye; [Inal, Ali] Mersin City Hosp, Dept Med Oncol, Mersin, Turkiye; [Guren, Ali Kaan] Marmara Univ, Dept Med Oncol, Fac Med Hosp, Istanbul, Turkiye; [Yildirim, Nilgun] Elazig Med Hosp, Dept Med Oncol, Elazig, Turkiye; [Telli, Tugba Akin] Demiroglu Bilim Univ, Dept Med Oncol, Fac Med Hosp, Istanbul, Turkiye; [Danaci, Yurdagul; Aydin, Umut] Inonu Univ, Dept Med Oncol, Fac Med Hosp, Malatya, Turkiye; [Almuradova, Elvina] Imir Can Hosp, Dept Med Oncol, Izmir, Turkiyeen_US
dc.description.abstractSacituzumab govitecan (SG) is an antibody-drug conjugate approved for metastatic or unresectable locally advanced triple-negative breast cancer (mTNBC) after at least two prior systemic therapies, yet real-world evidence remains limited. We conducted a retrospective, multicenter study including 285 patients with unresectable locally advanced or metastatic TNBC treated with SG across 52 oncology centers in Turkey. Median progression-free and overall survival were 5.4 months (95% confidence interval [CI], 4.6-6.2) and 12.2 months (95% CI, 10.5-13.9), respectively, with a 12-month overall survival rate of 49.2%. The objective response rate and disease control rate in evaluable patients were 36.8% and 63.9%. Grades 3-4 adverse events, mainly neutropenia, occurred in 44.2% of patients. Dose reductions were needed in 20% of cases; no treatment-related deaths were reported. Our large real-world cohort reinforces the effectiveness and manageable safety profile of SG, mirroring pivotal trials, and highlights its value as a therapeutic option in diverse and heavily pretreated mTNBC populations.en_US
dc.description.woscitationindexScience Citation Index Expanded
dc.identifier.doi10.1002/ijc.70213
dc.identifier.issn0020-7136
dc.identifier.issn1097-0215
dc.identifier.pmid41147655
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1002/ijc.70213
dc.identifier.urihttps://hdl.handle.net/20.500.12712/39565
dc.identifier.wosWOS:001601304600001
dc.identifier.wosqualityQ1
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofInternational Journal of Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectReal-World Studyen_US
dc.subjectSacituzumab Govitecanen_US
dc.subjectTriple-Negative Breast Canceren_US
dc.titleReal-World Effectiveness and Safety of Sacituzumab Govitecan in Patients With Metastatic or Unresectable Locally Advanced Triple-Negative Breast Cancer: A Multicenter Study by the Turkish Oncology Groupen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files

Collections

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu